Published in PLoS One on February 12, 2016
Griffithsin: An Antiviral Lectin with Outstanding Therapeutic Potential. Viruses (2016) 0.75
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med (2005) 21.56
Growth of human hepatoma cells lines with differentiated functions in chemically defined medium. Cancer Res (1982) 11.72
Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J Virol (1999) 4.99
Formation and intracellular localization of hepatitis C virus envelope glycoprotein complexes expressed by recombinant vaccinia and Sindbis viruses. J Virol (1994) 4.21
Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system. Nat Biotechnol (2010) 3.44
Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs. Hepatology (2009) 3.10
Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. J Virol (2008) 2.74
Identification of amino acid residues in CD81 critical for interaction with hepatitis C virus envelope glycoprotein E2. J Virol (2000) 2.71
Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J Virol (2005) 2.19
Targeting the glycans of glycoproteins: a novel paradigm for antiviral therapy. Nat Rev Microbiol (2007) 2.07
Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. Hepatology (2006) 1.88
Advantages of a single-cycle production assay to study cell culture-adaptive mutations of hepatitis C virus. Proc Natl Acad Sci U S A (2008) 1.83
The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J Virol (2007) 1.69
Robust production of infectious viral particles in Huh-7 cells by introducing mutations in hepatitis C virus structural proteins. J Gen Virol (2007) 1.69
Characterization of the envelope glycoproteins associated with infectious hepatitis C virus. J Virol (2010) 1.59
Broad antiviral activity of carbohydrate-binding agents against the four serotypes of dengue virus in monocyte-derived dendritic cells. PLoS One (2011) 1.52
Identification of GBF1 as a cellular factor required for hepatitis C virus RNA replication. J Virol (2009) 1.43
From non-A, non-B hepatitis to hepatitis C virus cure. J Hepatol (2015) 1.43
Role of N-linked glycans in the functions of hepatitis C virus envelope proteins incorporated into infectious virions. J Virol (2010) 1.41
A concerted action of hepatitis C virus p7 and nonstructural protein 2 regulates core localization at the endoplasmic reticulum and virus assembly. PLoS Pathog (2011) 1.41
Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization. J Virol (2007) 1.34
Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans. J Biol Chem (2006) 1.32
Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus. Antiviral Res (2003) 1.29
In vitro selection of a neutralization-resistant hepatitis C virus escape mutant. Proc Natl Acad Sci U S A (2008) 1.25
Cell culture-adaptive mutations promote viral protein-protein interactions and morphogenesis of infectious hepatitis C virus. J Virol (2012) 1.24
Targeting the glycans of gp120: a novel approach aimed at the Achilles heel of HIV. Lancet Infect Dis (2005) 1.20
TaqMan amplification system with an internal positive control for HCV RNA quantitation. J Clin Virol (2004) 1.19
Mutations within a conserved region of the hepatitis C virus E2 glycoprotein that influence virus-receptor interactions and sensitivity to neutralizing antibodies. J Virol (2010) 1.19
Broad-spectrum in vitro activity and in vivo efficacy of the antiviral protein griffithsin against emerging viruses of the family Coronaviridae. J Virol (2009) 1.15
Griffithsin has antiviral activity against hepatitis C virus. Antimicrob Agents Chemother (2011) 1.14
Glycan shifting on hepatitis C virus (HCV) E2 glycoprotein is a mechanism for escape from broadly neutralizing antibodies. J Mol Biol (2013) 1.11
The hepatitis C virus glycan shield and evasion of the humoral immune response. Viruses (2011) 1.07
The origin of hepatitis C virus. Curr Top Microbiol Immunol (2013) 1.07
Antiviral lectins from red and blue-green algae show potent in vitro and in vivo activity against hepatitis C virus. PLoS One (2013) 1.03
Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions. Virology (2007) 0.98
Virology and cell biology of the hepatitis C virus life cycle: an update. J Hepatol (2014) 0.96
A cell culture adapted HCV JFH1 variant that increases viral titers and permits the production of high titer infectious chimeric reporter viruses. PLoS One (2012) 0.93
The variable regions of hepatitis C virus glycoprotein E2 have an essential structural role in glycoprotein assembly and virion infectivity. J Gen Virol (2010) 0.89
Inhibition of hepatitis C virus 3a genotype entry through Glanthus Nivalis Agglutinin. Virol J (2011) 0.87
Unexpected structural features of the hepatitis C virus envelope protein 2 ectodomain. J Virol (2014) 0.87
Structural basis for penetration of the glycan shield of hepatitis C virus E2 glycoprotein by a broadly neutralizing human antibody. J Biol Chem (2015) 0.85
Development of hepatitis C virus production reporter-assay systems using two different hepatoma cell lines. J Gen Virol (2012) 0.85
The cyanobacterial lectin scytovirin displays potent in vitro and in vivo activity against Zaire Ebola virus. Antiviral Res (2014) 0.84
Characterization of hepatitis C virus recombinants with chimeric E1/E2 envelope proteins and identification of single amino acids in the E2 stem region important for entry. J Virol (2012) 0.84
Natural selection of adaptive mutations in non-structural genes increases trans-encapsidation of hepatitis C virus replicons lacking envelope protein genes. J Gen Virol (2013) 0.83
Inhibition of hepatitis C virus by the cyanobacterial protein Microcystis viridis lectin: mechanistic differences between the high-mannose specific lectins MVL, CV-N, and GNA. Mol Pharm (2013) 0.82
Permissivity of primary human hepatocytes and different hepatoma cell lines to cell culture adapted hepatitis C virus. PLoS One (2013) 0.81
Inhibition of severe acute respiratory syndrome coronavirus replication in a lethal SARS-CoV BALB/c mouse model by stinging nettle lectin, Urtica dioica agglutinin. Antiviral Res (2011) 0.81
Cell culture-adaptive mutations in the NS5B gene of hepatitis C virus with delayed replication and reduced cytotoxicity. Virus Res (2009) 0.81
The euHCVdb suite of in silico tools for investigating the structural impact of mutations in hepatitis C virus proteins. Infect Disord Drug Targets (2009) 0.81
Cooperation between the Hepatitis C Virus p7 and NS5B Proteins Enhances Virion Infectivity. J Virol (2015) 0.78
Viral entry inhibition: too late for hepatitis C, but promising for other viral infections. Gut (2014) 0.77
Development of a simple system for screening anti-hepatitis C virus drugs utilizing mutants capable of vigorous replication. J Virol Methods (2010) 0.76
Apolipoprotein(a) inhibits hepatitis C virus entry through interaction with infectious particles. Hepatology (2017) 0.75
Hepatitis E Virus Lifecycle and Identification of 3 Forms of the ORF2 Capsid Protein. Gastroenterology (2017) 0.75